Sector News

Novartis CEO pledges not to sell Sandoz generics unit

July 29, 2019
Life sciences

Novartis Chief Executive Vas Narasimhan pledged in an interview published on Saturday not to sell the Swiss drugmaker’s generics unit Sandoz amid a revamp that has prompted speculation he is preparing to offload the business.

“No, we will not sell Sandoz,” Narasimhan told the Sueddeutsche Zeitung newspaper. “We will make Sandoz autonomous within Novartis, so it’s more competitive. Our plan is to focus Sandoz and make it better in the long-term.”

Novartis is revamping Sandoz, a process Narasimhan has previously said will take roughly the next year and a half. He has already sold a generic U.S. pills business and dermatology assets that were under extreme price pressure, and has suggested other divestitures may be forthcoming.

These changes, along with the departure of Sandoz’s former CEO in March, have prompted some analysts to predict Narasimhan may eventually exit generics.

Sandoz, which last year had nearly $10 billion in sales, upgraded its full-year sales target on July 18, holding out the possibility of low-single-digit percentage sales growth, up from a previous prediction of “broadly in line” with 2018.

In the first half of 2018, Sandoz’s business with biosimilar copies of branded blockbusters in Europe helped offset a U.S. business that remains under price pressure.

Narasimhan also said he planned to keep both Sandoz and Hexal brands in Germany. “There will be no changes here,” he told the newspaper.

By John Miller

Source: Reuters

comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.